News
VRBCF
431.80
NaN%
--
Virbac Publishes Interim Financial Report for First Half of 2026
TipRanks · 09/17 19:02
Virbac lifts margins and confirms 2026 targets on strong animal health growth
TipRanks · 09/17 16:09
Virbac Updates Share Capital and Voting Rights Structure as of August 2026
TipRanks · 09/07 09:08
IDEXX Laboratories: Worth The Premium
Seeking Alpha · 08/08 12:00
Jefferies Keeps Their Hold Rating on Virbac SA (0NM7)
TipRanks · 07/13 14:06
Virbac SA (0NM7) Receives a Buy from Kepler Capital
TipRanks · 04/19 01:46
Kepler Capital Sticks to Their Buy Rating for Virbac SA (0NM7)
TipRanks · 03/20 01:55
Virbac expands pet health portfolio with £100M acquisition of feline hyperthyroidism drug from Norbrook
Seeking Alpha · 12/18/2025 07:37
More
Webull provides a variety of real-time VRBCF stock news. You can receive the latest news about Virbac SA through multiple platforms. This information may help you make smarter investment decisions.
About VRBCF
Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.